Natixis Advisors LLC Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Natixis Advisors LLC decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 35.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 159,437 shares of the medical research company’s stock after selling 85,699 shares during the quarter. Natixis Advisors LLC owned approximately 0.09% of IQVIA worth $31,331,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Synergy Asset Management LLC purchased a new stake in shares of IQVIA in the fourth quarter worth about $33,000. Avior Wealth Management LLC raised its holdings in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. raised its holdings in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Meeder Asset Management Inc. raised its holdings in IQVIA by 353.7% in the 3rd quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock worth $58,000 after purchasing an additional 191 shares during the period. Finally, Versant Capital Management Inc raised its holdings in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on IQV shares. Bank of America reduced their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. JPMorgan Chase & Co. reduced their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Stifel Nicolaus reduced their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Robert W. Baird reduced their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Finally, Truist Financial reissued a “buy” rating and set a $263.00 target price (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Up 2.2 %

Shares of IQVIA stock opened at $185.40 on Monday. The firm has a market capitalization of $32.69 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a 50 day moving average of $196.63 and a 200 day moving average of $210.43.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.